Neuralink

Neuralink

Implantable Brain-Computer Interface | Fremont, California | Founded 2016

Neuralink is pioneering the development of the world's most advanced implantable brain-computer interface (BCI), enabling direct communication between the human brain and external devices. The company's N1 implant - featuring over 1,024 electrode channels on ultra-thin flexible threads - has already demonstrated the ability to enable a paralyzed patient to control a computer cursor and play chess using thought alone. With a $9 billion valuation, over $1.2 billion in total funding, and a pipeline extending from paralysis treatment to vision restoration and ultimately human-AI symbiosis, Neuralink occupies a unique position at the frontier of neurotechnology. For investors considering buying Neuralink stock in the private market, the company represents one of the most transformational deep-technology opportunities in existence.

Company Overview

Founded	2016
Headquarters	Fremont, California
Industry	Biotechnology / Brain-Computer Interface
Total Funding	$1.2+ billion
Current Valuation	$9 billion (January 2026) [1]
Revenue Stage	Pre-commercial / Clinical-stage
Employee Count	201–500
Website	neuralink.com

Highlights for Neuralink

• First human implant performed in January 2024; patient Noland Arbaugh demonstrated the ability to control a computer mouse and play chess through thought alone. [2]
• Raised $650 million in January 2026, bringing its valuation to $9 billion and total primary funding to over $1.2 billion. [1]
• FDA granted Investigational Device Exemption (IDE) approval for a new clinical trial in October 2025 to test thought-to-text translation capabilities. [2]
• Launched human trials for a vision restoration device (Blindsight) in January 2026, targeting the hundreds of millions of blind and visually impaired individuals worldwide. [2]
• N1 Link features over 1,024 electrode channels - more than any competing BCI device - providing significantly greater precision in neural signal capture. [3]
• Preparing for mass production; Elon Musk has stated the implant could eventually cost $1,000–$2,000 at volume, compared to $40,000 today. [2]
• Backed by leading investors including Founders Fund, ARK Invest, Sequoia Capital, Thrive Capital, Lightspeed, and G42. [1]

Product & Technology

Core Offerings:

• N1 Implant (PRIME Study): A coin-sized neural implant featuring 1,024+ electrodes on ultra-thin, flexible threads, inserted into the brain by a specialized surgical robot through an 8mm skull opening. Wirelessly transmits neural signals to external devices, currently enabling computer cursor control, text communication, and web browsing for paralyzed patients. [3]
• Blindsight: A second-generation BCI device designed to restore vision by bypassing damaged eyes and sending visual information directly to the brain's visual cortex. Human trials commenced in early 2026. [2]
• Surgical Robot: A specialized neurosurgical robot capable of precisely inserting electrode threads while avoiding surface blood vessels. The system is designed to enable a 10-minute outpatient procedure at scale. [3]

Technology Stack:

• Ultra-thin flexible electrode threads (thinner than a human hair) with 1,024+ electrodes per device. [3]
• Wireless real-time neural signal transmission and spike detection algorithms. [3]
• Computer vision-guided precision surgical robotics. [3]
• MemoryAlloy-style signal processing for real-time brain-computer translation. [3]

Competitive Advantages

• Electrode Count Leadership: Neuralink's 1,024+ channel device surpasses all competitors, including Blackrock Neurotech's Utah Array, enabling significantly more precise neural communication. [3]
• Flexible Threads: The thin, flexible electrode design minimizes brain tissue displacement and immune response compared to rigid array competitors. [3]
• Integrated System: Neuralink's vertically integrated approach - combining implant hardware, surgical robotics, and neural decoding software - creates a comprehensive clinical solution that competitors must replicate entirely to compete. [3]
• Musk Network Effects: Elon Musk's global profile and relationships with regulatory bodies, governments, and capital markets provide Neuralink with fundraising, talent, and commercial access unavailable to any competitor. [2]

Market Opportunity

Neuralink's initial target market - individuals with quadriplegia and paralysis - affects over 5 million Americans and tens of millions globally. The global market for neurological disorder treatments exceeds $80 billion annually, while psychiatric medications generate over $40 billion in sales. Longer-term applications in vision restoration (hundreds of millions of blind/visually impaired globally), hearing restoration, and neurological disease treatment expand the addressable market into the hundreds of billions. The most speculative but largest opportunity - consumer neural enhancement - represents a potential multi-trillion-dollar market if Neuralink achieves its vision of consumer-accessible BCI at $1,000–$2,000 per device. [4]

Market Trends:

• Growing regulatory openness to innovative medical devices with breakthrough designation pathways.
• Increasing investment in neurotechnology as brain-computer interfaces validate clinical utility.
• AI convergence with BCI - using LLMs to decode neural signals - accelerating capability development. [2]
• Aging global population increasing the prevalence of paralysis, blindness, and neurological disorders. [4]

Financial Overview

Revenue Stage: Neuralink is a clinical-stage company with no material commercial revenue as of early 2026. The company is currently in human clinical trials for the PRIME Study (paralysis) and has initiated Blindsight human trials. [3]

Business Model: Neuralink will initially generate revenue through sales of implantable BCI systems to hospitals at an estimated total cost of approximately $40,000 per patient (hardware ~$10,000; surgical procedure and support ~$30,000). At scale, Elon Musk has stated a goal of reducing the implant cost to $1,000–$2,000 through consumer electronics-style manufacturing scaling and a streamlined 10-minute outpatient procedure. [2]

Funding History and Investment Rounds

Key Investors: Founders Fund, GigaFund, GV (Google Ventures), Valor Equity Partners, DFJ Growth, ARK Invest, Sequoia Capital, Thrive Capital, Lightspeed, G42 [1][5]

Round	Amount	Total Raised	Valuation	Notable Investors
Early Stage VC	$107M	$107M	$127M	Founders Fund, GigaFund
Early Stage VC II	$51M	$158M	$521M	GV
Series C	$205M	$363M	$2.1B	Valor Equity Partners, Vy Capital, GV
Series D	$323M	$686M	$3.5B	ARK Invest, Sequoia Capital
Series E	$600M+	$1.2B+	$9B	Thrive Capital, Lightspeed, G42

Leadership Team

• Jared Birchall, Co-CEO, CFO & President: Previously Senior Vice President of Private Wealth Management at Morgan Stanley, Private Wealth Advisor at Merrill Lynch, and Financial Analyst at Goldman Sachs. B.S. Brigham Young University. [6]
• Elon Musk, Co-Founder & Co-CEO: CEO of SpaceX and Tesla; Founder of X.com (PayPal), SolarCity, The Boring Company, and xAI. B.A. University of Pennsylvania. [6]
• Paul Merolla, Co-Founder: Previously a Research Scientist at IBM's neuromorphic computing division. Ph.D., Postdoctoral Research Fellowship, Stanford University; M.S. Bioengineering, University of Pennsylvania. [6]
• Dongjin Seo, VP of Implant & Founding Member: Previously Graduate Student Researcher at UC Berkeley. B.S. Electrical Engineering, Caltech; Ph.D. EECS, UC Berkeley. [6]

Investment Considerations

Growth Drivers:

• PRIME Study clinical validation: Successful human trials de-risk the regulatory pathway and build physician confidence for commercial adoption. [2]
• Blindsight vision restoration device opens a global market of hundreds of millions of blind and visually impaired individuals. [2]
• Manufacturing scale ambitions: Moving from $40,000 per device toward $1,000–$2,000 consumer pricing could expand the addressable market exponentially. [2]
• Downstream applications in psychiatric disorders ($40B+ market), neurological diseases ($80B+ market), and consumer enhancement. [2]

Risks and Challenges:

• Regulatory risk: FDA approval for novel brain implants involves multi-year clinical trials; adverse events could halt progress indefinitely. [2]
• Technical reliability: Early implants showed thread retraction from brain tissue - a known challenge of long-term neural implant stability. [2]
• Ethical and social scrutiny: Neuralink faces ongoing scrutiny over animal welfare practices and broader concerns about data privacy for neural data. [2]

Future Outlook:

• Planned expansion from paralysis to vision, hearing, and psychiatric disorder applications over the next 5 years. [2]
• First patient may receive an upgrade and/or dual implant, demonstrating iterative improvement. [2]
• Long-term consumer enhancement vision ("AI symbiosis") positions Neuralink for a potential multi-trillion-dollar future market. [2]

References

[1] Source: Reuters.com / Bloomberg.com

[2] Source: Sacra.com

[3] Source: Neuralink.com

[4] Source: Bloomberg.com / WHO

[5] Source: Pitchbook.com

[6] Source: LinkedIn.com

Rainmaker Securities, LLC ("RMS") is a FINRA (FINRA.org) registered broker-dealer and SIPC (SIPC.org) member. Find this broker-dealer and its agents at brokercheck.finra.org. Our relationship summary can be found at rainmakersecurities.com/disclosures.

RMS is engaged by its clients to make referrals to buyers or sellers of private securities ("Securities"). If such client closes a Securities transaction with a buyer or seller so referred, RMS is entitled to a success fee from the client. Such success fee may be in the form of cash or in warrants to purchase securities of the client or client's affiliate. RMS or RMS representatives may hold equity in its issuer clients or in the issuers of securities purchased or sold by the parties to a transaction.

This communication is confidential and is addressed only to its intended recipient. This communication does not represent an offer or solicitation to buy or sell Securities. Such an offer must be made via definitive legal documentation by the seller of securities.